Journal
DRUG DELIVERY
Volume 29, Issue 1, Pages 1212-1231Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10717544.2022.2058652
Keywords
Alpha-arbutin; chitosan nanoparticles; collagen; hyaluronic acid; clinical model for melasma
Categories
Ask authors/readers for more resources
This study developed functionalized chitosan nanoparticles (CSNPs) in gel form for enhanced topical delivery of alpha-arbutin to treat melasma. The CSNPs demonstrated positive zeta potential, high entrapment efficiency, good stability, and sustained release of alpha-arbutin. In vitro and clinical evaluations showed that the CSNPs hydrogel had better therapeutic efficacy compared to the free drug hydrogel, making it a promising modality for melasma treatment.
The increase in the production of melanin level inside the skin prompts a patient-inconvenient skin color disorder namely; melasma. This arouses the need to develop efficacious treatment modalities, among which are topical nano-delivery systems. This study aimed to formulate functionalized chitosan nanoparticles (CSNPs) in gel form for enhanced topical delivery of alpha-arbutin as a skin whitening agent to treat melasma. Ionic gelation method was employed to prepare alpha-arbutin-CSNPs utilizing a 2(4) full factorial design followed by In vitro, Ex vivo and clinical evaluation of the nano-dispersions and their gel forms. Results revealed that the obtained CSNPs were in the nanometer range with positive zeta potential, high entrapment efficiency, good stability characteristics and exhibited sustained release of alpha-arbutin over 24 h. Ex vivo deposition of CSNPs proved their superiority in accumulating the drug in deep skin layers with no transdermal delivery. DSC and FTIR studies revealed the successful amorphization of alpha-arbutin into the nanoparticulate system with no interaction between the drug and the carrier system. The comparative split-face clinical study revealed that alpha-arbutin loaded CSNPs hydrogels showed better therapeutic efficacy compared to the free drug hydrogel in melasma patients, as displayed by the decrease in: modified melasma area and severity index (mMASI) scores, epidermal melanin particle size surface area (MPSA) and the number of epidermal monoclonal mouse anti-melanoma antigen recognized by T cells-1 (MART-1) positive cells which proved that the aforementioned system is a promising modality for melasma treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available